Adenocarcinoma
暂无分享，去创建一个
[1] M. Pennell,et al. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose , 2013, BMC Veterinary Research.
[2] D. Thamm,et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. , 2012, Journal of veterinary internal medicine.
[3] D. Thamm,et al. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. , 2011, Journal of veterinary internal medicine.
[4] S. Dow,et al. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. , 2008, Journal of veterinary internal medicine.
[5] N. Shenoy,et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.